AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Anti-Toxins / Neutralizing ricin

Neutralizing ricin

August 29, 2017 By antoxa

AntoXa is using the vivoXPRESS® system to produce an innovator antibody (PhD9) being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.

Ricin is a naturally occurring toxin from the Castorbean plant. It is considered a category B threat agent by the U.S. Centers for Disease Control and Prevention due to its accessibility, ease of production and extreme lethality. No therapeutic antibody or vaccine is currently available to counteract its deadly effects. The PhD9 antibody drug candidate developed by DRDC prevents ricin from penetrating cells.

DRDC has conducted in vitro and in vivo studies that found the plant-made version of the antibody showed therapeutic efficacy against ricin intoxication that was comparable to hD9 produced using mammalian cell technology. The findings were presented at the Antibody Engineering and Therapeutics Conference in December 2015.

Learn more about AntoXa’s product pipeline.

Filed Under: Anti-Toxins

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2022 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates